Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

Clinical trial NCT04310943 · COMPLETED

Trial details

NCT number: NCT04310943
Sponsor: Zhou Chengzhi
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Adenocarcinoma Stage IV

Start date: 2021-03-01
Primary completion: 2023-06-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.